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Abstract
Mitochondrial unfolded protein response (UPRmt) is an adaptive transcriptional
response induced by damaged proteins accumulated in mitochondria. UPRmt signaling
involves induction of mitochondrial specific chaperones and proteases such as HSP60,
LonP1 and ClpP, aiding in the restoration of mitochondrial protein pool homeostasis.
However, the cell-protective roles of UPRmt in the context of mitochondrial stress-induced
cell death in AML has not been well explored. We demonstrate that AML cells are
susceptible to mitochondrial targeted agents such as ONC201, an agonist of the
mitochondrial protease ClpP, and gamitrinib, an inhibitor of mitochondrial chaperone
TRAP1, however, these agents also induce activating transcription factor 5 (ATF5), a
primary mediator of UPRmt in mammals. Thus, we hypothesized that inactivating the cellprotective UPRmt pathway, by inhibiting ATF5, could potentially sensitize AML cells to
mitochondrial stress. Consistently, flow cytometry-based apoptosis assays demonstrated that
stable knockdown of ATF5 by short-hairpin RNA (shRNA) sensitized AML cells to single
treatments of ONC201 and gamitrinib. In contrast, ATF5 knockdown did not further enhance
AML cell killing when these agents were combined with the BCL2 inhibitor venetoclax,
suggesting that venetoclax combination may overcome the cell-protective response of UPRmt.
However, tetracycline-inducible shRNA against ATF5 did not sensitize AML cells to any of
the above treatments. Similarly, pharmacological inhibition of ATF5 function by cell
penetrating peptide Dpep was also unable to sensitize AML cells to mitochondrial targeted
agents, suggesting that short-term inactivation of ATF5 is not sufficient to abrogate its cellprotective functions. Of note, while knockdown of ATF5 gene expression was confirmed in
both stable and transient short hairpin models, canonical downstream genes of UPRmt (e.g.,
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LONP1 and HSPD1) were not significantly affected in neither model, suggesting a
disconnect between ATF5 expression and regulation of UPRmt gene expression, perhaps
uniquely in AML cells.
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Introduction
Mitochondria are responsible for cellular bioenergetics and metabolite production
necessary for cell growth and proliferation (1). Another important role of mitochondria is the
regulation of apoptosis, a programmed cell death pathway mediated by proapoptotic Bcl-2
family members and pharmacologically inducible by BH3 mimetics. One such BH3 mimetic
is venetoclax, a specific inhibitor of the anti-apoptotic protein Bcl-2. Venetoclax is FDA
approved for AML, in combination with hypomethylating agents or cytarabine (2).
Additionally, AML cells have greater copy numbers of mitochondrial DNA and higher rates
of oxygen consumption in comparison to normal hematopoietic stem cells (HSCs),
suggesting a greater reliance on mitochondria (3). Mitochondrial metabolites involved in
glucose metabolism are also reported to have prognostic value in AML (4). Thus,
mitochondria are a potential therapeutic target in AML. Indeed, AML cells have been shown
to be vulnerable to mitochondrial targeted agents such as inhibitors of mitochondrial
respiratory chain complex I (e.g., IACS-010759), potent agonists of mitochondrial
caseinolytic protease P (ClpP) (ONC201 and ONC212), an inhibitor of mitochondrial-

1

specific heat shock protein-75 (HSP75) (gamitrinib), and inhibitor of mitochondrial importer
mia40 (MitoBlock6) (Figure 1B) (2, 5, 6).
While AML cells are sensitive to mitochondrial targeted agents, mitochondrial
dysfunction induced by mitochondrial targeted agents also triggers mitochondrial unfolded
protein response (UPRmt), a protective and adaptive transcriptional response induced upon
cellular crisis by damaged proteins when mitochondrial protein compositions or folding
conditions are dysregulated (8, 9). UPRmt signaling involves transcriptional induction of
mitochondrial specific chaperones and proteases including HSP60 (HSPD1), HSP70
(HSPA9), LonP1 (LONP1) and ClpP, some of which are highly expressed in various cancers
including AML, promoting mitochondrial protein pool homeostasis and repair (9). Previous
studies have shown that expression of these UPRmt induced chaperones and proteases
contributes to tumor growth and survival, whereas their inhibition enhances apoptosis and
reduced tumor cell proliferation (10,11).
Activating transcription factor 5 (ATF5), a bZip family transcription factor, has
recently been proposed as a main regulator of UPRmt in mammals (8, 9). ATF5 protein is
reported to contain both mitochondrial localization and nuclear localization sequences.
Previous studies propose that under normal physiological conditions, ATF5 accumulates in
mitochondria, while under mitochondrial stress conditions ATF5 instead accumulates in the
nucleus, activating transcription of downstream UPRmt genes and aiding in restoration of
mitochondrial protein pool homeostasis (Figure 1A) (9, 12). ATF5 is considered oncogenic
in several cancers, including glioblastoma, breast carcinoma, leukemia and lung
adenocarcinoma. Targeting and depletion of ATF5 in glioblastoma results in tumor
regression and growth inhibition (12). We have previously reported that mitochondrial stress
2

inducers such as ONC201, Tigecycline (inhibitor of mitochondrial ribosomal EF-Tu), and
MitoBlock6 induce high levels of ATF5 gene expression in AML cell lines (7). Thus, ATF5mediated UPRmt signaling could be protective against mitochondrial targeted agents in AML
cells, and inactivation of ATF5 possibly sensitize AML cells to mitochondrial targeted
agents. The cell-protective roles of ATF5-regulated UPRmt against mitochondrial targeted
agents in AML cells have not been well explored. Here we hypothesize that ATF5 regulates
UPRmt which protects AML cells from mitochondrial targeted therapies.
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Figure 1. Overview of ATF5 regulation of UPRmt.
(A) Proposed cellular mechanism of UPRmt mediation by ATF5. (B) mitochondrial targeted agents explored in this study
and their molecular targets.
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Material and Methods:
Cells and culture conditions:
OCI-AML3, MOLM13 and MV4;11 cells were grown and maintained in RPMI-1640
with 10% fetal bovine serum (FBS). HEK-293T cells were grown in Dulbecco’s Modified
Eagle Medium (DMEM) with 10% FBS. Cell lines were previously confirmed to be
mycoplasma negative by DNA fingerprinting (5).
Cell viability and apoptosis assays:
AML cell lines OCI-AML3, MOLM13 and MV4;11 were seeded at 1.5 x 105 per mL
in either 24-well or 96-well plates for 72-hour timepoint apoptosis assays with venetoclax
(chemgood), ONC201 (MedChemExpress), gamitrinib (obtained from Dr. Altieri at the
Wistar Institute) and Dpep (details below). For tetracycline-inducible shRNA models
targeting ATF5, AML cell lines were first pre-treated with tetracycline for 48 hours before
treatment with ONC201, gamitrinib and venetoclax along with continuous tetracycline
induction. Cells were seeded at 1.5x 105 / mL initial concentration and passaged at a ratio of
1:4 after 48 hours to avoid over-confluency and spontaneous cell death due to extended
experimental timepoints.
In all apoptosis experiments, final cell concentration in untreated wells were adjusted
to be < 1.6 x106 per mL to avoid over-growth and spontaneous cell death. For apoptosis
analysis, Annexin V and DAPI binding assays were performed using flow cytometry.
Annexin V-negative and/or DAPI-negative populations were considered live cells, while
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Annexin V-positive and Annexin V/DAPI-double-positive populations were categorized as
apoptotic cells.
Dpep was purchased from AlanScientific in acetate salt form with the following
sequence RQIKIWFQNRRMKWKKLVELSAENEKLHQRVEQLTRDLAGLRQFFK (14).
Peptide was dissolved in sterile 10% glycerol dH20 and aliquoted for storage at -80 Celsius.
Immunoblotting
Cell line lysates were extracted using 2% SDS protein lysis buffer (2% SDS, 10%
glycerol, 0.02% BPB, 4% 2-ME in 0.25M pH 6.8 Tris-HCL) with added phosphatase
protease inhibitor (Cell Signaling) at 2 x106 cells / 100uL. SDS-Page was performed using
Bio-Rad 10% or 12% pre-cast gels and quantified with Odyssey imaging system. Antibody
used: ATF5 (Invitrogen), -Actin (sigma)
Real-time PCR
mRNA was extracted from 1-2 x106 OCI-AML3, MOLM13 and MV4;11 cells with
Qiagen RNeasy kit. Single-strand cDNA were generated using SuperScript™ III First-Strand
Synthesis System Super Mix from extracted mRNA. RT-PCR was performed on 96-well
plates with TaqMan fluorophore probes and TaqMantm Fast Advanced Master Mix using
Thermofisher QuantStudio 3 instrument.
Lentiviral infection and ATF5 knock down models.
Mature shRNA sequences targeting ATF5 (“38” and “42”) are as follows:
TRCN0000017638: AAGTCTTCCATCTGTTCCAGC, TRCN0000017642:
AAGTCCAGAGTATCCAAGACA. Vectors of stable-expression ATF5 shRNA clone 38
and 42 in PLKO.1 backbone was directly purchased from vendor (Dharmacon). Tetracycline-
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inducible model of shATF5 clone 38 vector was generated by removing the stuffer between
restriction sites AgeI and EcoRI then ligating the ATF5 shRNA sequence between the
restriction sites on tet-on PLKO.1 backbone, which contains an upstream Tetracycline
response element (TRE) followed by puromycin-resistance element for selection.
Lentivirus of both stable and tet-on shATF5 models were generated by transfecting
pMD2.G and psPAX2 together with shATF5 vector in HEK-293T cells using JetPrime
transfection reagent according to manufacturer’s protocol. After 5 hours, culture media of
transfected HEK-293T cells were replaced with 10% FBS Iscove’s DMEM as virus
producing media. Lentivirus containing supernatant was collected after 48 hours of
incubation. OCI-AML3, MOLM13 and MV4;11 cells were infected for 24 hours using viral
supernatant along with polybrene (OCI-AML3- 8ug/mL, MOLM13 6ug/mL, MV4;11
6ug/mL). After viral incubation, polybrene containing virus media were washed out by
centrifugation at 200xg for 10 minutes. Infected cells were then incubated in 10% FBS
RPMI-1640 media for approximately two doubling times before beginning puromycin
selection at initial concentration of 0.5ug/mL. Selection of transformed cells was concluded
when cells reached 95% viability under 1ug/mL puromycin treatment.

7

RESULTS

Figure 2. Stable Knockdown of ATF5 Sensitizes AML Cells to Mitochondrial targeted agents.
(A) RT-PCR confirmation of ATF5 knockdown in OCI-AML3 cells transduced with short-hairpin ATF5 scramble control,
clone 38 and clone 42 PLKO.1 vector. Cells were treated with tetracycline 8ug/mL for 48 hours to induce ATF5 expression.
(B). Western blot of stable expression shATF5 clone 38 transduced OCI-AML3 cells. ATF5 is expected at 31kDa, but
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detected band is at 35 kDa. (C). Apoptosis and Live cell % of OCI-AML3 shATF5 clone 38 cells after 72 hours of ONC201
treatment. (D) RT-PCR of ATF5 and UPRmt genes using newly generated stable expression shATF5 clone 38 OCI-AML3,
MOLM13 and MV4;11 cell lines. (E) Apoptosis effect of mitochondrial targeted agents (ONC201, venetoclax,
gamitrinib(G-TPP)) in shATF5 MOLM13, OCI-AML3 and MV4;11 cells compared to scramble control after 72 hours.
False positive adjusted p-value (q-value) *<0.01, **<0.001, ***<0.0001, ****<0.00001. (F) RT-PCR verification of ATF5
and UPRmt gene expression induced by classical UPRmt inducer gamitrinib(G-TPP) in OCI-AML3 cells after 6hr treatment.

Stable knockdown of ATF5 sensitizes AML cells to mitochondrial targeted agents.
To explore the effects of genetic knockdown of ATF5 in AML cell lines and their
sensitivity to mitochondrial targeted agents, we designed a stable expression model of
shRNA targeting ATF5. For initial assessment, OCI-AML3 cells were transformed with two
shRNAs, shATF5 38 and shATF5 42 by lentiviral infection. Stable expression of shATF5 38
significantly downregulated ATF5 mRNA expression in OCI-AML3 cells and inhibited highdose tetracycline-induced ATF5 upregulation (Figure 2A). Confirmation of ATF5 reduction
at the protein level was unsuccessful, possibly due to the unreliable anti-ATF5 antibody as
the molecular weight of detected bands did not match the expected 31 kDa molecular weight
(Figure 2B). (There is no established anti-ATF5 antibody commercially available, per
personal conversation with Dr. Cole M. Haynes, an expert of UPRmt in University of
Massachusetts Medical School.)
We have previously reported ONC201 as an inducer of ATF5 and UPRmt (7). OCIAML3 with stable expression of shATF5 (shATF5 OCI-AML3 cells) and control shRNA
(shC) were treated with ONC201 for cell death assay. shATF5 OCI-AML3 cells showed
significantly greater apoptosis and less proliferation with ONC201 treatment, compared to
those in shC OCI-AML3 cells (Figure 2C). Of note, in untreated conditions, shATF5 OCIAML3 cells showed higher spontaneous apoptosis and lower proliferation compared to
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scramble control, suggesting that ATF5 knockdown alone exerts anti-AML effects (Figure
2C).
To verify the sensitization of AML to mitochondrial targeted agents by ATF5
knockdown, we applied the shATF5 model also in MOLM13 and MV4;11 cells and
generated another clone of OCI-AML3 shATF5 cells (Figure 2D), and cells were treated with
ONC201, gamitrinib and venetoclax. While varying among the three AML cell lines, data
show that stable expression of ATF5 knockdown sensitizes AML cells to mitochondrial
targeted agents. Specifically, shATF5 OCI-AML3 cells were more sensitive to ONC201 and
gamitrinib but not to venetoclax, compared to control cells; shATF5 MV4;11 were sensitive
to all three treatments, compared to control cells; and shATF5 MOLM13 was only slightly
more sensitive to gamitrinib treatment compared to control cells, and showed no significant
difference to the other two compounds (Figure 2E). Of note, although gamitrinib is an
established UPRmt inducer, changes in UPRmt genes observed in AML cells after gamitrinib
treatment were variable (Figure 2F). In OCI-AML3 cells, HSPD1 mRNA was upregulated by
gamitrinib while ATF5, LONP1 and HSPA9 mRNA were not. In MV4;11 cells, only ATF5
mRNA was upregulated while the other three genes are not affected.
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Figure 3. Transient tetracycline inducible ATF5 knockdown does not sensitize AML cells to mitochondria targeted
therapeutics.

(A) RT-PCR verification of tet-on ATF5 knockdown and UPRmt genes panel. OCI-AML3, MOLM13 and MV4;11 cells
were treated with tetracycline at indicated concentrations for 48 hours prior to lysate extraction. (B) RT-PCR of ATF5
knockdown efficacy and effects on UPRmt genes by dose-dependent and high-dose tetracycline treatment at 48hr timepoint.
(C) RT-PCR of ATF5 knockdown efficacy and effects on UPRmt genes by 24hr ONC201 treatment after 48 hours of
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tetracycline induction. (D) 72-hour apoptosis assay comparison between control and tet-on shATF5 OCI-AML3, MV4;11
and MOLM13 cells after treatment with ONC201. (E) 48-hour apoptosis assay comparison between control and tet-on
shATF5 OCI-AML3 and MV4;11 cells after treatment with gamitrinib(G-TPP).

Tetracycline-inducible ATF5 knockdown does not sensitize AML cells to mitochondria
targeted agents.
To test whether acute inactivation of ATF5 sensitizes AML to mitochondrial targeted
agents, we generated a tetracycline-inducible model of ATF5 knockdown by shRNA (tet-on
shATF5) which could potentially mimic pharmacological inhibition of ATF5. OCI-AML3,
MOLM13 and MV4;11 cells were transfected with tet-on shATF5 vector by lentiviral
infection. The cells were then treated with tetracycline to induce ATF5 knockdown, at a low
dose that is sufficient to induce expression of the shRNA, but not at the high dose used
previously to induce mtUPR. (Figure 3A). The tet-on shATF5 model in OCI-AML3 cells
was able to successfully knock down both basal and high-dose tet-induced ATF5 expression
(Figure 3B). Tet-on ATF5 was also able to knock down ONC201-induced ATF5 by
tetracycline treatment in a dose dependent manner (Figure 3C). Of note, increase or decrease
ATF5 gene expression by either knockdown or mitochondrial targeted agents did not change
expressions of downstream UPRmt genes significantly (Figure 3A-C). This suggest a possible
disconnection of ATF5 regulation and UPRmt genes in AML cells.
To evaluate the effect of transient ATF5 knockdown on killing of AML cells by
mitochondrial targeted agents, we pre-treated tet-on shATF5 OCI-AML3, MOLM13 and
MV4;11 cells with tetracycline to knock down ATF5, then treated with the cells with
ONC201 or gamitrinib. Contrary to results observed in the stable shATF5-expressing model
(Figure 2E), transient ATF5 knockdown by this inducible model did not sensitize OCIAML3, MOLM13 and MV4;11 cells to ONC201 treatment (Figure 3D). Similarly, transient
12

tet-on ATF5 knockdown did not sensitize OCI-AML3 and MV4;11 against gamitrinib
treatment compared to controls (Figure 3E), as opposed to the sensitization observed in stable
knockdown of ATF5 (Figure 2E). This finding suggests that stable knockdown of ATF5 may
have different biological phenotypes and UPRmt regulation compared to transient tet-on
ATF5 knockdown, possibly due to chronic depletion of ATF5.
Of note, a drawback of tet-on shATF5 model in our context of UPRmt is that
tetracycline at higher doses also acts as a UPRmt/ATF5 inducer, as tetracycline disrupts
mitochondrial protein translation. Indeed, even in shC cells, tetracycline caused synergistic
cell death in combination with ONC201 or gamitrinib, likely reflecting its inhibitory effects
on mitochondrial protein translation. However, even at the highest dose of 500ug/mL, we
confirmed that ATF5 knockdown is still successful compared to shC (Figure 3B-C),
indicating that the inducible knockdown system is functional and useful for the comparison
between shC vs shATF5 cells.
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Figure 4. Pharmacological inhibition of ATF5 by Dominant-negative Peptide of CEBPD Does Not Sensitize AML
Cells to Mitochondrial Targeted Agents
(A) Principle of Dpep’s functional inactivation of ATF5. (B) Apoptosis results of OCI-AML3 and MV4;11 parental cells
after 72 hours of Dpep + gamitrinib (G-TPP) /ONC201 combination treatment. Similar range of Dpep concentration was
used in a previous report on solid tumors such as breast cancers and glioblastoma which induced cell death (14).

14

Pharmacological inhibition of ATF5 by dominant-negative peptide CEBPD does not
sensitize AML cells to mitochondrial targeted agents.
We then tested if pharmacological inhibition of ATF5 would sensitize AML cells to
mitochondrial targeted agents. ATF5 must form dimers with another bZip transcription factor
to function. ATF5 does not form homodimers by itself, and instead forms heterodimers with
its binding partners CEBPD and CEBPB. Dpep, a cell penetrating, dominative-negative
peptide of ATF5’s binding partner CEBPD without a DNA binding domain can be used to
functionally inactivate ATF5 (Figure 4A) (14). To test cell killing effects of pharmacological
inhibition of ATF5 combined with mitochondrial targeted agents, we co-treated OCI-AML3
cells using Dpep with ONC201 or gamitrinib. Similar to transient genetic knockdown of
ATF5, Dpep co-treatment did not enhance apoptosis in OCI-AML3 and MV4;11 cells by
ONC201 or gamitrinib (Figure 4B). These data suggest that pharmacological inactivation of
ATF5 does not sensitize AML cells to mitochondrial targeted agents, consistent with the
findings with transient tet-on shATF5 knockdown.
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Figure 5. Stable knockdown of ATF5 Did not Sensitize AML Cells to Venetoclax Combination Treatment with
Mitochondria Targeted Therapeutics.
(A) Apoptosis and live cell data of MV4;11 with or without stable ATF5 knockdown when treated with venetoclax and GTPP/ONC201 for 72 hours. (B) Apoptosis and live cell data of OCI-AML3 with or without stable ATF5 knockdown when
treated with venetoclax and gamitrinib (G-TPP) for 72 hours.

Stable knockdown of ATF5 did not sensitize AML cells to venetoclax combination
treatment with mitochondria targeted agents
Venetoclax is often used in the clinic in combination therapies with other therapeutics
such as azacitidine or cytarabine, since single agent venetoclax treatment only exhibits
modest activity in AML (15). We have previously reported that venetoclax synergizes with
various mitochondrial targeted agents such as ONC201, tigecycline and MitoBlock6 in AML
cell lines (7). Venetoclax is also synergistic in vivo and in vitro in combination with
ONC212, a more potent analogue of ONC201 (16). While transient genetic and
pharmacological inactivation of ATF5 did not sensitize AML cells to mitochondrial targeted
agents, we further examined if stable ATF5 knockdown would sensitize AML cells to
venetoclax in combination with mitochondria targeted agents. OCI-AML3 and MV4;11 were
treated with venetoclax in combination with ONC201 or gamitrinib. While venetoclax
exhibited strong apoptogenic synergism in combination with both ONC201 and gamitrinib as
expected, stable ATF5 knockdown did not further enhance the efficacy of combination
therapies (Figure 5A, B), suggesting that the potent synergy induced by these combinations
can overcome ATF5-mediated cell-protective effects.

Discussion:
In this study, we have shown that stable shATF5 knockdown sensitized AML cells to
individual mitochondrial targeted agents but not when combined with venetoclax in vitro.
16

Thus, ATF5 gene expression potentially protects AML cells against mitochondrial targeted
agents, while the potent synergy induced by the combination with venetoclax could
overcome the ATF5-mediated cell-protective response.
Also, an unexpected finding was that upregulated ATF5 expression by mitochondrial
targeted agents in AML did not significantly enhance the expressions of UPRmt downstream
genes (e.g., 3F, 3B and 3C), making it challenging for us to validate the functional
inactivation of ATF5 in our knockdown models in the present study. Both stable and
transient knockdown of ATF5 also did not significantly decrease UPRmt gene expression,
suggesting a disconnect between ATF5 and UPRmt, and that ATF5 gene expression level
does not directly regulate proposed downstream UPRmt gene expression. A potential
explanation of the disconnect between ATF5 upregulation and downstream effects is that
AML cells have a unique ATF5-independent regulation of UPRmt genes. Previous studies on
ATF5-mediated UPRmt used HeLa and HEK-293T cells, thus the discrepancy we observed
in this study may be tissue- or tumor-type-dependent. Further investigation of downstream
genes by more comprehensive screening such as microarray or RNA-sequencing using our
ATF5 knockdown cells would be useful to address this hypothesis. As a future direction,
rather than targeting ATF5, knockdown or knockout of specific UPRmt downstream genes
such as LONP1 or HSP70 could be used to study UPRmt mediated protection against
mitochondrial targeted agents in the context of AML.
There was a difference in phenotype between transient and stable ATF5 knockdown in
terms of AML cell sensitivity to cell death induction by mitochondrial targeted agents. Teton ATF5 knockdown, while successfully suppressing ATF5 gene expression, did not
sensitize AML cells to the mitochondrial targeted agents while stable ATF5 knockdown did,
17

using the same agents in the same AML cell lines. This suggests that chronic depletion of
ATF5 could be the key factor to mitochondrial targeted agents’ sensitization of AML, by
inducing unexplored genetic or proteomic changes. Under steady state conditions, ATF5
protein is reported to have a very short half-life due to protease-dependent and caspasedependent mechanisms, but its stability can be greatly enhanced by chaperone HSP70 (17).
This suggests the possibility that a short, transient knockdown of ATF5 may not be sufficient
to deplete remaining ATF5 protein bound to stabilizing chaperones. A CRISPR-cas9 ATF5
knockout model could provide more reliable ATF5 depletion for future investigations.
Results from pharmacological inhibition of ATF5, however, do not support this possibility as
Dpep functionally inhibits ATF5, yet still did not enhance AML cell sensitivity to
mitochondrial targeted agents. Dpep concentration used in AML testing was able to induce
cell death in solid tumor models such as melanoma and glioblastoma (14).
The proof of concept in this study relies on transcript levels of ATF5 alone, as there is no
validated, published antibody to ATF5. Previous studies of ATF5 and UPRmt used antibodies
generated in individual laboratory and are unavailable commercially (8). Future studies on
this topic should be augmented with working ATF5 specific antibodies, or by genetically
inserting FLAG epitopes into the ATF5 locus for protein level assessment
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